A guide to drug discovery: Logistics of process R&D: transforming laboratory methods to manufacturing scale

In the past, process R&D — which is responsible for producing candidate drugs in the required quantity and of the requisite quality — has had a low profile, and many people outside the field remain unaware of the challenges involved. However, in recent years, the increasing pressure to achieve shorter times to market, the demand for considerable quantities of candidate drugs early in development, and the higher structural complexity — and therefore greater cost — of the target compounds, have increased awareness of the importance of process R&D. Here, I discuss the role of process R&D, using a range of real-life examples, with the aim of facilitating integration with other parts of the drug discovery pipeline.

[1]  P. Jaksch,et al.  An efficient synthesis of a new, chiral 2',6'-pipecoloxylidide local anaesthetic agent , 1987 .

[2]  Federsel.  Building bridges from process R&D: from a customer-supplier relationship to full partnership. , 2000, Pharmaceutical science & technology today.

[3]  P. Grubb.  Patents for Chemicals, Pharmaceuticals and Biotechnology: Fundamentals of Global Law, Practice and Strategy , 1999 .

[4]  Alan D. Curzons,et al.  Solvent selection guide: a guide to the integration of environmental, health and safety criteria into the selection of solvents , 1999 .

[5]  Neal G. Anderson,et al.  Practical Process Research & Development , 2000 .

[6]  H -J. Federsel.  Drug discoverers -you need us! , 2001, Drug discovery today.

[7]  I. Ojima,et al.  Catalytic Asymmetric Synthesis , 1993 .

[8]  Hans-Ulrich Blaser,et al.  Enantioselective catalysis in fine chemicals production. , 2001, Chemical communications.

[9]  Hans-Jürgen Federsel.  Development of a Process for a Chiral Aminochroman Antidepressant: A Case Story† , 2000 .

[10]  Hans-Jürgen Federsel.  Start small, think big — the art of process R&D , 2002, Nature Reviews Drug Discovery.

[11]  Karlheinz Drauz,et al.  Enzyme Catalysis in Organic Synthesis , 1995 .

[12]  J. Kuhlmann.  Drug research: from the idea to the product. , 1997, International journal of clinical pharmacology and therapeutics.

[13]  E. Anderson,et al.  Two of a kind: diverse presentations of the same disease. , 2002, Chest.

[14]  Walter Cabri,et al.  From Bench to Market: The Evolution of Chemical Synthesis , 2000 .

[15]  Hans-Jürgen Federsel,et al.  Facing chirality in the 21st century: Approaching the challenges in the pharmaceutical industry. , 2003, Chirality.

[16]  K. Gadamasetti.  Process Chemistry in the Pharmaceutical Industry , 1999 .

[17]  George M. Whitesides,et al.  Enzymes in Synthetic Organic Chemistry , 1994 .

[18]  C. Gerhardt.  Untersuchungen über die wasserfreien organischen Säuren , 1853 .

[19]  B. Trost,et al.  The atom economy--a search for synthetic efficiency. , 1991, Science.

[20]  F. Ettinger.  Two of a kind. , 2001, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[21]  Per Lindberg,et al.  A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole , 2003, Nature Reviews Drug Discovery.

[22]  Wolfgang A. Herrmann,et al.  Applied Homogeneous Catalysis with Organometallic Compounds , 1996 .

[23]  David J. C. Constable,et al.  Metrics to ‘green’ chemistry—which are the best? , 2002 .

[24]  Oljan Repič.  Principles of Process Research and Chemical Development in the Pharmaceutical Industry , 1998 .

[25]  Hanna Cotton,et al.  Asymmetric synthesis of esomeprazole , 2000 .

[26]  Barry M. Trost,et al.  Atom Economy—A Challenge for Organic Synthesis: Homogeneous Catalysis Leads the Way , 1995 .